GSI treatment of CD34+ primary CML cells resulted in Hes1 downregulation; however, it failed to show any effect in two CML samples (CML-1 and CML-6). This evidence concerns the gene HES1 and chronic myelogenous leukemia, BCR-ABL1 positive.